Citations

Clear

14 citation(s) found for "Anderson, Laura".

Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation
Cardell, Chelsea F. , Segovia, Diana, Prakash, Laura R. , Zemla, Tyler , Shi, Qian , Ahmad, Syed, Snyder, Rebecca A. , O'Reilly, Eileen M , Katz, Matthew H G , Snyder, Rebecca A , Shi, Qian , Zemla, Tyler J , Segovia, Diana, Prakash, Laura R. , Herman, Joseph M. , O’Reilly, Eileen M. , Katz, Matthew H. G. , Snyder, Rebecca A.

Mayo Clinic

JCO Oncology Practice | July 22, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1200/op-25-01431 | PMID 42485590 Get It

PURPOSE Adherence to operative standards and thorough documentation of surgical technique are critical, particularly in multidisciplinary clinical trials. We sought to evaluate variability in the performance and documentation of oncologically relevant aspects of technical surgery among patients enrolled in Alliance A021501, a phase 2 National Clinical Trials Network randomized clinical trial of neoadjuvant therapy for borderline resectable pancreatic adenocarcinoma. METHODS We reviewed the primary operative and pathology reports of all enrolled patients who underwent complete pancreatic resection. Operative techniques and pathologic end points with potential to influence recurrence and survival were evaluated. RESULTS Fifty-one of 126 study participants (40.5%) underwent complete pancreatectomy. The extent of lymphadenectomy was documented in 36 (70.6%) operative reports, and 5 (9.8%) reports outlined the specific lymph node stations removed. Periadventitial dissection of the superior mesenteric artery was described in 25 of 50 (50.0%) operative reports. Immediate histopathologic analysis of the hepatic duct and pancreatic parenchyma margins was documented in 29 of 50 (58.0%) and 32 of 49 (65.3%) reports, respectively, and presence or absence of residual disease following resection was documented in 9 of 51 (17.6%) reports. Specimen orientation was documented in 19 of 51 (37.3%) pathology reports, and 30 of 49 (61.2%) pathology reports stated the distance between the tumor and final SMA margin. CONCLUSION Even in this rigorously controlled, multicenter, randomized pancreatic cancer clinical trial, performance of key elements of technical surgery was inconsistent, and documentation was incomplete. Standardization of technique and documentation in clinical trials and within clinical practice should be addressed to improve quality assurance and trial interpretability.
Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study
Chalitsios, Christos V. , Markozannes, Georgios , Aglago, Elom K. , Berndt, Sonja I., Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B., Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Schmit, Stephanie L. , Steinfelder, Robert S. , Ugai, Tomotaka, Zaidi, Syed Hassan Ejaz , Woods, Michael O. , Andreson, Laura, Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K, Berndt, Sonja I , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Schoen, Robert E , Woods, Michael O , Brenner, Hermann , Anderson, Laura , Pellatt, Andrew J , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Berndt, Sonja I. , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Obón‐Santacana, Mireia , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Schoen, Robert E. , Brenner, Hermann , Pellatt, Andrew J. , Tsilidis, Konstantinos K.

Mayo Clinic

JNCI Cancer Spectrum | September 29, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf095 | PMID 41031512 Get It

Abstract Background Physical activity is associated with lower colorectal cancer (CRC) risk, but its association with molecular subtypes defined by genetic and epigenetic alterations of the disease is unclear. Such information may enhance the understanding of the mechanisms related to the benefits of physical activity. Methods Pooled observational (cases: n = 5386; controls: n = 6798; studies n = 5) and genome-wide association data (cases: n = 8178; controls: n = 10 472; studies n = 5) were used. We used multivariable logistic regression models and Mendelian randomization to assess the association between physical activity and the risk of CRC subtypes defined by individual tumor markers (and marker combinations), namely microsatellite instability status, CpG island methylator phenotype status, and BRAF and KRAS mutations. We used case-only analysis to test for differences between molecular subtypes. We applied Bonferroni correction to account for multiple tests. Results In the pooled observational analysis, higher levels of physical activity were associated with lower CRC risk (Obs-per 1SD, odds ratio [OR] = 0.94, 95% confidence interval [CI] = 0.90 to 0.97), with an association that was stronger in males (Obs-per 1SD, OR = 0.91, 95% CI = 0.87 to 0.96) than in females (Obs-per 1SD, OR = 0.97, 95% CI = 0.91 to 1.03; Pinteraction = .04). Higher physical activity was associated with a lower risk of CRC across all molecular subtypes, especially in males. There was no difference in the associations by subtypes by pooled observational or Mendelian randomization analyses. The findings did not differ by study design, anatomical site, and early or late age onset of CRC. Conclusions Our findings suggest that physical activity is not differentially associated with the 4 major molecular subtypes involved in colorectal carcinogenesis, indicating that its benefits extend broadly across colorectal cancer pathogenesis.
Plasma Ghrelin and Risks of Sex-Specific, Site-Specific, and Early-Onset Colorectal Cancer: A Mendelian Randomization Analysis
Hazelwood, Emma , Manzano, Catalina Lopez , Vincent, Emma E. , Albanes, Demetrius , Bishop, D. Timothy , Marchand, Loı̈c Le , Peters, Ulrike , Murphy, Gwen , Samadder, N. Jewel , Guelpen, Bethany Van , Papadimitriou, Nikos , Lopez Manzano, Catalina , Bishop, D Timothy , Marchand, Loïc Le , Ulrich, Cornelia M , Peters, Ulrike , Murphy, Gwen , Samadder, N Jewel , Anderson, Laura , Gunter, Marc J , Murphy, Neil , Van Guelpen, Bethany , Papadimitriou, Nikos , Vincent, Emma E , Albanes, Demetrius , Hazelwood, Emma , Ulrich, Cornelia M. , Anderson, Laura N. , Gunter, Marc J. , Murphy, Neil

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 3, 2024 | Volume: 33 | Issue: 12 | Pages: 1727-1732

10.1158/1055-9965.epi-24-0926 | PMID 39361354 Get It

Abstract Background: Epidemiological and laboratory-based studies have provided conflicting evidence for a role of ghrelin in colorectal cancer development. We conducted two-sample Mendelian randomization (MR) analyses to evaluate evidence for an association of circulating ghrelin and colorectal cancer risk overall and by sex, cancer subsite, and age at diagnosis. Methods: Genetic instruments proxying plasma total ghrelin levels were obtained from a recent genome-wide association study of 54,219 participants. Summary data for colorectal cancer risk were obtained from a recent meta-analysis of several genetic consortia (up to 73,673 cases and 86,854 controls). A two-sample MR approach and several sensitivity analyses were applied. Results: We found no evidence for an association of genetically predicted plasma total ghrelin levels and colorectal cancer risk (0.95, 95% confidence interval, 0.81–1.12; R2 of ghrelin genetic instruments: 4.6%), with similarly null results observed when stratified by sex, anatomical subsite, and for early-onset colorectal cancer. Conclusions: Our study suggests that plasma ghrelin levels are unlikely to have a causal relationship with overall, early-onset, and sex- and cancer subsite–stratified colorectal cancer risk. Impact: This large-scale analysis adds to the growing body of evidence that plasma total ghrelin levels are not associated with colorectal cancer risk.
Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers
Klomp, Jennifer E. , Stalnecker, Clint A. , Bryant, Kirsten L. , Edwards, A. Cole , Drizyte‐Miller, Kristina , Hibshman, Priya S. , Diehl, J. Nathaniel , Lee, Ye S. , Morales, Alexis Jean , Taylor, Khalilah E. , Peng, Sen, Tran, Nhan L. , Prevatte, Alex W., Hover, Laura D. , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Olson, Peter , Christensen, James G. , Graves, Lee M. , Wennerberg, Krister , Klomp, Jeffrey A , Klomp, Jennifer E , Stalnecker, Clint A , Bryant, Kirsten L , Drizyte-Miller, Kristina , Diehl, J Nathaniel , Lee, Ye S , Morales, Alexis J , Taylor, Khalilah E , Herring, Laura E , Barker, Natalie K , Hallin, Jill , Chowdhury, Saikat , Coker, Oluwadara , Lee, Hey Min , Goodwin, Craig M , Gautam, Prson , Olson, Peter , Christensen, James G , Shen, John P , Kopetz, Scott , Graves, Lee M , Lim, Kian-Huat , Wang-Gillam, Andrea , Wennerberg, Krister , Cox, Adrienne D , Der, Channing J , Tran, Nhan L , Herring, Laura E. , Barker, Natalie K. , Gautam, Prson , Kopetz, Scott , Wang‐Gillam, Andrea , Cox, Adrienne D.

Mayo Clinic

Science | June 6, 2024 | Volume: 384 | Issue: 6700 | Pages: No page available

10.1126/science.adk0775 | PMID 38843331 Get It

How the KRAS oncogene drives cancer growth remains poorly understood. Therefore, we established a systemwide portrait of KRAS- and extracellular signal–regulated kinase (ERK)–dependent gene transcription in KRAS-mutant cancer to delineate the molecular mechanisms of growth and of inhibitor resistance. Unexpectedly, our KRAS-dependent gene signature diverges substantially from the frequently cited Hallmark KRAS signaling gene signature, is driven predominantly through the ERK mitogen-activated protein kinase (MAPK) cascade, and accurately reflects KRAS- and ERK-regulated gene transcription in KRAS-mutant cancer patients. Integration with our ERK-regulated phospho- and total proteome highlights ERK deregulation of the anaphase promoting complex/cyclosome (APC/C) and other components of the cell cycle machinery as key processes that drive pancreatic ductal adenocarcinoma (PDAC) growth. Our findings elucidate mechanistically the critical role of ERK in driving KRAS-mutant tumor growth and in resistance to KRAS-ERK MAPK targeted therapies.
Genome-wide association study identifies high-impact susceptibility loci for HCC in North America
Hassan, Manal M. , Li, Donghui , Han, Younghun , Choi, Jiyeon , Kelley, Robin Kate , Bracci, Paige M. , Bucur, Roxana , Ghobrial, R. Mark , Santella, Regina M. , Nguyen, Mindie H. , Liu, Geoffrey , Parikh, Neehar D. , Wu, Hui‐Chen , El‐Serag, Hashem B. , Chang, Ping , Li, Yanan , Chun, Yun Shin , Lee, Sunyoung S. , Gu, Jian , Hawk, Ernest T. , Huff, Chad , Rashid, Asif , Amin, Hesham M. , Beretta, Laura , Wolff, Robert A. , Antwi, Samuel O. , Patt, Yehuda Z., Hwang, Lu‐Yu, Schmidt, Mikayla A. , White, Donna L. , Goss, John A. , Khaderi, Saira, Marrero, Jorge A. , Cigarroa, Francisco , Roberts, Lewis R. , Han, Younghun , Roberts, Lewis R , Antwi, Samuel O , Liu, Geoffrey , Parikh, Neehar D , Beretta, Laura , Gu, Jian , Byun, Jinyoung , Hatia, Rikita , Long, Erping , Cleary, Sean P. , Lok, Anna S. , Permuth, Jennifer B. , Yuan, Jian-Min , Singal, Amit G. , Jalal, Prasun K. , Kono, Yuko , Shah, Dimpy P. , Nguyen, Mindie H. , Kim, Richard D. , Li, Yanan, Sun, Ryan , Klein, Alison P. , Zhang, Karen , Shah, Pankil , Kaseb, Ahmed O , Amos, Christopher I.

Mayo Clinic

Hepatology | February 21, 2024 | Volume: 80 | Issue: 1 | Pages: 87-101

10.1097/hep.0000000000000800 | PMID 38381705 Get It

Background and Aims: Despite the substantial impact of environmental factors, individuals with a family history of liver cancer have an increased risk for HCC. However, genetic factors have not been studied systematically by genome-wide approaches in large numbers of individuals from European descent populations (EDP). Approach and Results: We conducted a 2-stage genome-wide association study (GWAS) on HCC not affected by HBV infections. A total of 1872 HCC cases and 2907 controls were included in the discovery stage, and 1200 HCC cases and 1832 controls in the validation. We analyzed the discovery and validation samples separately and then conducted a meta-analysis. All analyses were conducted in the presence and absence of HCV. The liability-scale heritability was 24.4% for overall HCC. Five regions with significant ORs (95% CI) were identified for nonviral HCC: 3p22.1, MOBP, rs9842969, (0.51, [0.40–0.65]); 5p15.33, TERT, rs2242652, (0.70, (0.62–0.79]); 19q13.11, TM6SF2, rs58542926, (1.49, [1.29–1.72]); 19p13.11 MAU2, rs58489806, (1.53, (1.33–1.75]); and 22q13.31, PNPLA3, rs738409, (1.66, [1.51–1.83]). One region was identified for HCV-induced HCC: 6p21.31, human leukocyte antigen DQ beta 1, rs9275224, (0.79, [0.74–0.84]). A combination of homozygous variants of PNPLA3 and TERT showing a 6.5-fold higher risk for nonviral-related HCC compared to individuals lacking these genotypes. This observation suggests that gene-gene interactions may identify individuals at elevated risk for developing HCC. Conclusions: Our GWAS highlights novel genetic susceptibility of nonviral HCC among European descent populations from North America with substantial heritability. Selected genetic influences were observed for HCV-positive HCC. Our findings indicate the importance of genetic susceptibility to HCC development.
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP -Deleted Cancer
Engstrom, Lars D. , Aranda, Ruth , Waters, Laura , Moya, Krystal , Bowcut, Vickie , Vegar, Laura , Trinh, David , Hebbert, Allan , Smith, Christopher R. , Kulyk, Svitlana , Lawson, J. David , He, Leo , Hover, Laura D. , Hallin, Jill , Vanderpool, Darin , Briere, David M. , Blaj, Alice , Arbour, Kathryn C. , Jänne, Pasi A. , Papadopoulos, Kyriakos P. , Henry, Jason T. , Leventakos, Konstantinos , Christensen, James G. , Shazer, Ronald , Olson, Peter , Fernandez-Banet, Julio , Hallin, Jill , Vanderpool, Darin , Briere, David M , Blaj, Alice , Marx, Matthew A , Rodon, Jordi , Offin, Michael , Arbour, Kathryn C , Johnson, Melissa L , Kwiatkowski, David J. , Jänne, Pasi A , Haddox, Candace L , Papadopoulos, Kyriakos P , Henry, Jason T , Leventakos, Konstantinos , Christensen, James G , Shazer, Ronald , Olson, Peter , Johnson, Melissa L. , Haddox, Candace L.

Mayo Clinic

Cancer Discovery | August 8, 2023 | Volume: 13 | Issue: 11 | Pages: 2412-2431

10.1158/2159-8290.cd-23-0669 | PMID 37552839 Get It

Abstract Previous studies implicated protein arginine methyltransferase 5 (PRMT5) as a synthetic lethal target for MTAP-deleted (MTAP del) cancers; however, the pharmacologic characterization of small-molecule inhibitors that recapitulate the synthetic lethal phenotype has not been described. MRTX1719 selectively inhibited PRMT5 in the presence of MTA, which is elevated in MTAP del cancers, and inhibited PRMT5-dependent activity and cell viability with >70-fold selecti­vity in HCT116 MTAP del compared with HCT116 MTAP wild-type (WT) cells. MRTX1719 demonstrated dose-dependent antitumor activity and inhibition of PRMT5-dependent SDMA modification in MTAP del tumors. In contrast, MRTX1719 demonstrated minimal effects on SDMA and viability in MTAP WT tumor xenografts or hematopoietic cells. MRTX1719 demonstrated marked antitumor activity across a panel of xenograft models at well-tolerated doses. Early signs of clinical activity were observed including objective responses in patients with MTAP del melanoma, gallbladder adenocarcinoma, mesothelioma, non–small cell lung cancer, and malignant peripheral nerve sheath tumors from the phase I/II study. Significance: PRMT5 was identified as a synthetic lethal target for MTAP del cancers; however, previous PRMT5 inhibitors do not selectively target this genotype. The differentiated binding mode of MRTX1719 leverages the elevated MTA in MTAP del cancers and represents a promising therapy for the ∼10% of patients with cancer with this biomarker. See related commentary by Mulvaney, p. 2310. This article is featured in Selected Articles from This Issue, p. 2293
Gender Differences in a Mouse Model of Hepatocellular Carcinoma Revealed Using Multi-Modal Imaging
Engel, Brian J. , Paolillo, Vincenzo , Uddin, Md Nasir , Gonzales, Kristyn, McGinnis, Kathryn M., Patnana, Madhavi , Grindel, Brian J., Gores, Gregory J. , Piwnica‐Worms, David , Beretta, Laura , Pisaneschi, Federica , Millward, Steven W. , Gores, Gregory J. , Sutton, Margie N , Piwnica-Worms, David , Beretta, Laura , Pisaneschi, Federica , Gammon, Seth T , Millward, Steven W

Mayo Clinic

Cancers | July 27, 2023 | Volume: 15 | Issue: 15 | Pages: 3787

10.3390/cancers15153787 | PMID 37568603 Get It

The worldwide incidence of hepatocellular carcinoma (HCC) continues to rise, in part due to poor diet, limited exercise, and alcohol abuse. Numerous studies have suggested that the loss or mutation of PTEN plays a critical role in HCC tumorigenesis through the activation of the PI3K/Akt signaling axis. The homozygous knockout of PTEN in the livers of mice results in the accumulation of fat (steatosis), inflammation, fibrosis, and eventually progression to HCC. This phenotype bears a striking similarity to non-alcoholic steatohepatitis (NASH) which is thought to occupy an intermediate stage between non-alcoholic fatty liver disease (NAFLD), fibrosis, and HCC. The molecular and physiological phenotypes that manifest during the transition to HCC suggest that molecular imaging could provide a non-invasive screening platform to identify the hallmarks of HCC initiation prior to the presentation of clinical disease. We have carried out longitudinal imaging studies on the liver-specific PTEN knockout mouse model using CT, MRI, and multi-tracer PET to interrogate liver size, steatosis, inflammation, and apoptosis. In male PTEN knockout mice, significant steatosis was observed as early as 3 months using both magnetic resonance spectroscopy (MRS) and computed tomography (CT). Enhanced uptake of the apoptosis tracer 18F-TBD was also observed in the livers of male PTEN homozygous knockout mice between 3 and 4 months of age relative to heterozygous knockout controls. Liver uptake of the inflammation tracer [18F]4FN remained relatively low and constant over 7 months in male PTEN homozygous knockout mice, suggesting the suppression of high-energy ROS/RNS with PTEN deletion relative to heterozygous males where the [18F]4FN liver uptake was elevated at early and late time points. All male PTEN homozygous mice developed HCC lesions by month 10. In contrast to the male cohort, only 20% (2 out of 10) of female PTEN homozygous knockout mice developed HCC lesions by month 10. Steatosis was significantly less pronounced in the female PTEN homozygous knockout mice relative to males and could not accurately predict the eventual occurrence of HCC. As with the males, the [18F]4FN uptake in female PTEN homozygous knockout mice was low and constant throughout the time course. The liver uptake of 18F-TBD at 3 and 4.5 months was higher in the two female PTEN knockout mice that would eventually develop HCC and was the most predictive imaging biomarker for HCC in the female cohort. These studies demonstrate the diagnostic and prognostic role of multi-modal imaging in HCC mouse models and provide compelling evidence that disease progression in the PTEN knockout model is highly dependent on gender.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-4
Mayer, Erica L. , Fesl, Christian , Hlauschek, Dominik, Garcia-Estevez, Laura, Burstein, Harold J., Wette, Viktor, Miller, Kathy D., Balic, Marija, Mayer, Ingrid A. , Cameron, David , Winer, Eric P., Lorenzo, José Juan Ponce , Lake, Diana, Pristauz-Telsnigg, Gunda, Haddad, Tufia C. , Shepherd, Lois, Cardoso, Fátima , Sabanathan, Dhanusha, Breitenstein, Urs, Ackerl, Kerstin, Zehetner, Karin, Solomon, Kadine, El-Abed, Sarra , Theall, Kathy Puyana, Lu, Dongrui R. , Dueck, Amylou C. , Miller, Kathy D. , Hlauschek, Dominik , Zdenkowski, Nicholas , Mayer, IA , Cameron, David , Ponce Lorenzo, José Juan , Haddad, Tufia C , Iwata, Hiroji , Goetz, Matthew P , Cardoso, Fatima , Traina, Tiffany A , Metzger Filho, Otto , El-Abed, Sarra , Lu, Dongrui R , Dueck, A. C. , Gnant, Michael , DeMichele, Angela , Mayer, Erica L , Miller, Kathy D , Fesl, Christian , Garcia-Estevez, Laura, Burstein, Harold J., Wette, Viktor, Miller, Kathy D., Balic, Marija, Winer, Eric P., Lake, Diana, Pristauz-Telsnigg, Gunda, Shepherd, Lois, Sabanathan, Dhanusha, Breitenstein, Urs, Ackerl, Kerstin, Zehetner, Karin, Solomon, Kadine, Theall, Kathy Puyana

Mayo Clinic

Journal of Clinical Oncology | January 7, 2022 | Volume: 40 | Issue: 5 | Pages: 449-458

10.1200/jco.21.01918 | PMID 34995105 Get It

PURPOSE The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS. METHODS Patients with stage II-III HR+, HER2– disease were randomly assigned to 2 years of palbociclib with adjuvant ET versus ET alone. The primary objective was to compare iDFS between arms. Continuous monitoring of toxicity, dose modifications, and early discontinuation was performed. Association of baseline covariates with time to palbociclib reduction and discontinuation was analyzed with multivariable competing risk models. Landmark and inverse probability weighted per-protocol analyses were performed to assess the impact of drug persistence and exposure on iDFS. RESULTS Of the 5,743 patient analysis population (2,840 initiating palbociclib), 1,199 (42.2%) stopped palbociclib before 2 years, the majority (772, 27.2%) for adverse effects, most commonly neutropenia and fatigue. Discontinuation of ET did not differ between arms. Discontinuations for non–protocol-defined reasons were greater in the first 3 months of palbociclib, and in the first calendar year of accrual, and declined over time. No significant relationship was seen between longer palbociclib duration or ≥ 70% exposure intensity and improved iDFS. In the weighted per-protocol analysis, no improvement in iDFS was observed in patients receiving palbociclib versus not (hazard ratio 0.89; 95% CI, 0.72 to 1.11). CONCLUSION Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure. However, the discontinuation rate illustrates the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies.
Abstract CT111: Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Reyes-Uribe, Laura , Wu, Wenhui , Gelincik, Ozkan , Solis, Luisa M., Lynch, Patrick M. , Lim, Ramona M., Samadder, N. Jewel , Mork, Maureen E. , Marnett, Lawrence J. , Vornik, Lana A. , Liu, Diane D. , Kopelovich, Levy, Wistuba, Ignacio I. , Lee, J. Jack, Shoemaker, Robert H. , Perloff, Marjorie , Brown, Powell H., Lipkin, Steven M. , Bommi, Prashant V. , Francisco‐Cruz, Alejandro , Stoffel, Elena M. , Kanth, Priyanka , Taggart, Melissa W. , Milne, Ginger L. , Revuelta, María V. , Chang, Kyle , You, Y. Nancy , Lee, J. Jack, Sei, Shizuko , Szabó, Éva , Richmond, Ellen S. , Umar, Asad , Perloff, Marjorie, Vilar, Eduardo

Mayo Clinic

Cancer Research | September 4, 2020 | Volume: 80 | Issue: 16_Supplement | Pages: CT111-CT111

10.1158/1538-7445.am2020-ct111 Get It

Abstract Patients diagnosed with germline mutations in MMR genes (Lynch Syndrome, LS) have up to 70-80% lifetime risk of colorectal cancer. Therefore, this high-risk population has the potential to benefit from effective chemopreventive strategies. Naproxen is an NSAID widely used for pain treatment with an excellent safety profile that has demonstrated to be more efficacious preventing colorectal cancer compared to aspirin in vivo using an intestinal tissue-specific mouse model of LS (VC-Msh2-LoxP). The ‘Naproxen trial' was designed to evaluate the modulation of PGE2 levels in colorectal mucosa, evaluate safety and tolerability, and discover novel molecular pathways involved in the chemopreventive activity of naproxen in LS patients. Methods: Participants were randomized to naproxen 440 mg (HD), 220 mg (LD) and placebo by mouth daily for 6 months. Modulation of prostaglandin levels, number of adverse events (AEs) observed in each treatment arm and gene expression profiles by next-generation sequencing (mRNAseq) in normal colorectal mucosa of LS patients after 6 months of intervention were examined. Results: Eighty participants diagnosed with LS were randomized, 25 participants to HD, 27 to LD, and 28 to placebo. From these patients, 54 were considered evaluable per-protocol analysis: 16 in the HD group, 15 in the LD and 23 in placebo. The level of prostaglandin E2 in the colorectal mucosa decreased significantly after treatment with both LD and HD naproxen when compared to placebo (-91.2%±14.1, -93.6%±7.9, and 23.8%±108.4, P-value<0.001, respectively). Moreover, levels of PGE2 urinary metabolite (PGE-M) were significantly changed in both treatment groups when compared to placebo (-47.7%±56.9, -41.1%±40.5, 7.6%±94.3, P-Value<0.018). The intervention was well tolerated, no severe AEs related to treatment were reported, and the total number of AEs was not different across treatment arms. LD and HD naproxen promoted the activity of the immune system by activating different immune cell types without any effect on lymphoid cellularity and changed the expression patterns of the intestinal crypt towards epithelial differentiation and stem cell regulation. Conclusions: Naproxen is a promising strategy for immune interception in LS that induces immune-modulation coupled with changes in the dynamics of the intestinal crypt. We have also discovered naproxen-induced gene expression profiles for their potential use as predictive biomarkers of drug activity. Citation Format: Laura Reyes Uribe, Wenhui Wu, Ozkan Gelincik, Prashant V. Bommi, Alejandro Francisco-Cruz, Luisa M. Solis, Patrick M. Lynch, Ramona Lim, Elena Stoffel, Priyanka Kanth, N. Jewel Samadder, Maureen E. Mork, Melissa W. Taggart, Ginger L. Milne, Lawrence J. Marnett, Lana Vornik, Diane D. Liu, Maria Revuelta, Kyle Chang, Y. Nancy You, Levy Kopelovich, Ignacio I. Wistuba, J. Jack Lee, Shizuko Sei, Robert H. Shoemaker, Eva Szabo, Ellen Richmond, Asad Umar, Marjorie Perloff, Powell H. Brown, Steven M. Lipkin, Eduardo Vilar. Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr CT111.
Naproxen chemoprevention promotes immune activation in Lynch syndrome colorectal mucosa
Reyes-Uribe, Laura , Wu, Wenhui , Gelincik, Ozkan , Bommi, Prashant V. , Solis, Luisa M., Lynch, Patrick M, Lim, Ramona M., Kanth, Priyanka , Samadder, N. Jewel , Mork, Maureen E. , Marnett, Lawrence J. , Vornik, Lana A. , Liu, Diane D. , Kopelovich, Levy, Wistuba, Ignacio I. , Lee, J Jack, Sei, Shizuko , Shoemaker, Robert H. , Szabó, Éva , Perloff, Marjorie , Lipkin, Steven M. , Lee, J. Jack , Kanth, Priyanka , Revuelta, Maria , Vilar, Eduardo , Szabo, Eva , Bommi, Prashant , Lee, J Jack , Francisco‐Cruz, Alejandro , Lynch, Patrick M, Stoffel, Elena M. , Taggart, Melissa W. , Milne, Ginger L. , Revuelta, María V. , Chang, Kyle , You, Y. Nancy , Lee, J Jack, Richmond, Ellen S. , Umar, Asad , Perloff, Marjorie, Brown, Powel H.

Mayo Clinic

Gut | July 8, 2020 | Volume: 70 | Issue: 3 | Pages: 555-566

10.1136/gutjnl-2020-320946 | PMID 32641470 Get It

Objective Patients with Lynch syndrome (LS) are at markedly increased risk for colorectal cancer. It is being increasingly recognised that the immune system plays an essential role in LS tumour development, thus making an ideal target for cancer prevention. Our objective was to evaluate the safety, assess the activity and discover novel molecular pathways involved in the activity of naproxen as primary and secondary chemoprevention in patients with LS. Design We conducted a Phase Ib, placebo-controlled, randomised clinical trial of two dose levels of naproxen sodium (440 and 220 mg) administered daily for 6 months to 80 participants with LS, and a co-clinical trial using a genetically engineered mouse model of LS and patient-derived organoids (PDOs). Results Overall, the total number of adverse events was not different across treatment arms with excellent tolerance of the intervention. The level of prostaglandin E2 in the colorectal mucosa was significantly decreased after treatment with naproxen when compared with placebo. Naproxen activated different resident immune cell types without any increase in lymphoid cellularity, and changed the expression patterns of the intestinal crypt towards epithelial differentiation and stem cell regulation. Naproxen demonstrated robust chemopreventive activity in a mouse co-clinical trial and gene expression profiles induced by naproxen in humans showed perfect discrimination of mice specimens with LS and PDOs treated with naproxen and control. Conclusions Naproxen is a promising strategy for immune interception in LS. We have discovered naproxen-induced gene expression profiles for their potential use as predictive biomarkers of drug activity. Trial registration number gov Identifier: NCT02052908